European Society CD Meeting – highlights

This week marked the Manchester UK, European Society of Contact Dermatitis Meeting 14-17 September 2016…  There was so much top notch research presented  by international researchers.

Poster P016: Octylisothiazolinone is a relevant nonoccupational contact allergen in leather goods and may show cross-reactivity to methyisothiazolinone.   J. Leysen et al.

Poster P020: Airborne bullous allergic contact dermatitis from MI contained in a glass shower screen cleaning spray.  M.A Pastor-Nieto et al.

Poster P021: Allergic contact dermatitis from nickel is prevented using a novel barrier cream.  Niklasson B and Isaksson M.  New nickel prevention cream!  “We present a male worker with ACD due to exposure to nickel-containing tools and where an active barrier cream containing a strong metal chelating agent helped solved the problem.   … The leather gloves were analyzed for the release of nickel ions: one glove released 0.4ug nickel cm2 and the other 0.2ug nickel cm2. … The barrier cream, NIK-L-BLOKTM (Chemotechnique), captures the nickel ions using a strong chelating agent, diethylenetriaminepentaacetic acid, in a special formulation that immobilizes the nickel ions (as well as cobalt and chromium ions), thereby preventing allergic contact dermatitis.”

Poster P022 The methyisothiazolinone epidemic: a pan- European prospective study JF Schewensen et al. “Patients were exposed to the following products containing MI (and could be exposed to more than one category): dish-washing liquids (n=32), shampoo (n=30), bath/shower gel (n=22).  … Thirteen experienced an allergic reaction in newly painted rooms: ACD [skin] (n=11), rhinitis [nose] (n=2) and conjuncitivitis [eye] (n=1).  Eight (4.7%) experienced reactions to other airborne exposures than paint, for example cleaning agents… EFFECTIVE REGULATION OF MI IN COSMETIC AND OCCUPATIONAL PRODUCTS IS NOT YET IN PLACE.  The current data demonstrate the URGENT need for PREVENTIVE actions.”

These poster abstracts are printed and the articles are forthcoming.  It is critical to work with manufacturers, consumers, patient advocates (medical providers) and legislators to protect!!!